Phase 3 N=400 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Malignant Pleural Mesothelioma
Primary: Overall Survival (OS) — 8.5; 8.0 months — p=0.58
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=132 Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Head and Neck Carcinoma · Radiation-Induced Dermatitis
Primary: Radiation Dermatitis — 34; 36 Participants — p=.8872
Phase 3 N=83 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
Complicated Intra-abdominal Infection · Complicated Urinary Tract Infection
Primary: Percentage of Participants Experiencing ≥1 Adverse Events (AE) — 74.1 Percentage of Participants
Phase 3 N=118 VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic
Diabetic Foot Ulcer
Primary: Wound Closure by Week 15 — 10; 15; 9; 16 Participants — p=0.0517
Phase 3 N=517 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Phase 3 N=453 CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Acne Vulgaris
Primary: Investigator Global Assessment (IGA) Success Rate up to Week 52 — 453 Participants
Phase 3 N=124 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 22; 100 Participants
Phase 3 N=232 Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
Cancer · Pain
Primary: The Change of BFI-Bowel Function Index at visit8 — 48.3; 51.2 score on BFI
Phase 3 N=594 Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Breast Cancer · Metastases
Primary: Overall Survival — 9.1; 9.3 Months — p=0.673
Phase 3 N=326 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
Bipolar Disorder
Primary: Least Squares Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Score at Day 21 — 28.2; 27.9; -7.9; -10.3 Score on a Scale — p=0.0257
Phase 3 N=621 randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at End of Study (Week 12) — 365.37; 371.08; 395.80; 395.33 meters — p=0.2464
Phase 3 N=18 Extension Study for Patients Entered Into Study Infacort 003
Adrenal Insufficiency
Primary: Incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs) — 193; 9; 0; 42 adverse events
Phase 3 N=770 Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Breast Cancer
Primary: Progression Free Survival — 5.6; 4.3 Months — p=0.0426
Phase 3 N=19 Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
Systemic Juvenile Idiopathic Arthritis
Primary: Percentage of Participants Who Achieved a Minimum Adapted American College of Rheumatology (ACR) Pediatric 30 Criteria — 100.0 Percentage of Participants
Phase 3 N=120 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI90) at Week 24 — 10.0; 83.3 percentage of participants — p=< 0.001